Adriaan H de Jongste1, Teun van Gelder1, Jacoline E Bromberg1, Marieke T de Graaf1, Jan W Gratama1, Marco W Schreurs1, Herbert Hooijkaas1, Peter A Sillevis Smitt1. 1. Department of Neurology, Erasmus University Medical Center, Rotterdam, Netherlands (A.H.d.J., J.E.B., M.T.d.G., P.A.S.S.); Department of Medical Oncology, Erasmus University Medical Center, Rotterdam, Netherlands (A.H.d.J., J.W.G); Department of Hospital Pharmacy, Erasmus University Medical Center, Rotterdam, Netherlands (T.v.G.); Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands (T.v.G.); Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands (M.W.S., H.H.).
Abstract
BACKGROUND: Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNS patients improved their neurological outcome, we performed a prospective open-label, single-arm study on sirolimus. METHODS: Seventeen progressive Hu-PNS patients were treated with sirolimus with an intended treatment duration of 8 weeks. Primary outcome measures were (i) functional improvement, defined as a decrease of one or more points on the modified Rankin Scale (mRS), and (ii) improvement of neurological impairment, defined as an increase of one or more points on the Edinburgh Functional Impairment Tests (EFIT). RESULTS: One patient showed improvement on both clinical scales (mRS and EFIT). This patient presented with limbic encephalitis and improved dramatically from an mRS score of 3 to mRS 1. Another patient, with subacute sensory neuronopathy, remained stable at mRS 2 and improved one point on the EFIT scale. The other patients showed no improvement on the primary outcome measures. Median survival was 21 months. CONCLUSION: We conclude that treatment of Hu-PNS patients with sirolimus may improve or stabilize their functional disabilities and neurological impairments. However, the effects of this T cell-targeted therapy were not better than reported in trials on other immunotherapies for Hu-PNS. Trial Registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000793-20/NL.
BACKGROUND: Several lines of evidence suggest a T cell-mediated immune response in paraneoplastic neurological syndromes with anti-Hu antibodies (Hu-PNS). In order to investigate whether suppression of T cell-mediated immune responses in Hu-PNSpatients improved their neurological outcome, we performed a prospective open-label, single-arm study on sirolimus. METHODS: Seventeen progressive Hu-PNSpatients were treated with sirolimus with an intended treatment duration of 8 weeks. Primary outcome measures were (i) functional improvement, defined as a decrease of one or more points on the modified Rankin Scale (mRS), and (ii) improvement of neurological impairment, defined as an increase of one or more points on the Edinburgh Functional Impairment Tests (EFIT). RESULTS: One patient showed improvement on both clinical scales (mRS and EFIT). This patient presented with limbic encephalitis and improved dramatically from an mRS score of 3 to mRS 1. Another patient, with subacute sensory neuronopathy, remained stable at mRS 2 and improved one point on the EFIT scale. The other patients showed no improvement on the primary outcome measures. Median survival was 21 months. CONCLUSION: We conclude that treatment of Hu-PNSpatients with sirolimus may improve or stabilize their functional disabilities and neurological impairments. However, the effects of this T cell-targeted therapy were not better than reported in trials on other immunotherapies for Hu-PNS. Trial Registration https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-000793-20/NL.
Authors: Setareh Shams'ili; Janet de Beukelaar; Jan Willem Gratama; Herbert Hooijkaas; Martin van den Bent; Mars van 't Veer; Peter Sillevis Smitt Journal: J Neurol Date: 2006-01 Impact factor: 4.849
Authors: F van Broekhoven; M T de Graaf; J E Bromberg; H Hooijkaas; M J van den Bent; J W de Beukelaar; N A Khan; J W Gratama; J N van der Geest; M Frens; R Benner; P A Sillevis Smitt Journal: J Neurol Neurosurg Psychiatry Date: 2010-07-28 Impact factor: 10.154
Authors: Anna E M Bastiaansen; Adriaan H C de Jongste; Marienke A A M de Bruijn; Yvette S Crijnen; Marco W J Schreurs; Marcel M Verbeek; Daphne W Dumoulin; Walter Taal; Maarten J Titulaer; Peter A E Sillevis Smitt Journal: Neurooncol Adv Date: 2021-09-28
Authors: Jeffrey C Yeung; C Elizabeth Pringle; Harmanjatinder S Sekhon; Shaun J Kilty; Kristian Macdonald Journal: Case Rep Otolaryngol Date: 2016-09-07
Authors: John E Greenlee; Noel G Carlson; Justin R Abbatemarco; Ida Herdlevær; Stacey L Clardy; Christian A Vedeler Journal: Front Neurol Date: 2022-01-17 Impact factor: 4.003